163 related articles for article (PubMed ID: 22954465)
21. Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species.
Yazdanpanah S; Jabrodini A; Motamedi M; Zomorodian K; Kharazi M; Shabanzadeh S; Ghasemi F; Shariat S; Rezaei Arab M
Antonie Van Leeuwenhoek; 2023 Dec; 117(1):6. PubMed ID: 38153531
[TBL] [Abstract][Full Text] [Related]
22. Antifungal activity of propolis against Candida species isolated from cases of chronic periodontitis.
Siqueira AB; Rodriguez LR; Santos RK; Marinho RR; Abreu S; Peixoto RF; Gurgel BC
Braz Oral Res; 2015; 29():. PubMed ID: 26154370
[TBL] [Abstract][Full Text] [Related]
23. Study of fungal isolates in patients with chronic diarrhea at a tertiary care hospital in north India.
Banerjee P; Kaur R; Uppal B
J Mycol Med; 2013 Mar; 23(1):21-6. PubMed ID: 23375861
[TBL] [Abstract][Full Text] [Related]
24. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
25. [Species distribution and antifungal susceptibilities of yeast clinical isolates from three hospitals in Korea, 2001 to 2007].
Lee MK; Yong D; Kim M; Kim MN; Lee K
Korean J Lab Med; 2010 Aug; 30(4):364-72. PubMed ID: 20805708
[TBL] [Abstract][Full Text] [Related]
26. Clinical and mycological features of onychomycosis in central Tunisia: a 22 years retrospective study (1986-2007).
Dhib I; Fathallah A; Yaacoub A; Zemni R; Gaha R; Said MB
Mycoses; 2013 May; 56(3):273-80. PubMed ID: 23094998
[TBL] [Abstract][Full Text] [Related]
27. Candida Distribution in Onychomycosis and in vitro Susceptibility to Antifungal Agents.
Paškevičius A; Švedienė J; Kiverytė S; Bridžiuvienė D; Vaitonis G; Jablonskienė V
Acta Dermatovenerol Croat; 2020 Dec; 28(7):204-209. PubMed ID: 33834991
[TBL] [Abstract][Full Text] [Related]
28. Low
Abastabar M; Haghani I; Shokohi T; Hedayati MT; Aghili SR; Jedi A; Dadashi S; Shabanzadeh S; Hosseini T; Aslani N; Meis JF; Badali H
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224524
[TBL] [Abstract][Full Text] [Related]
29. Antibiofilm activity of propolis extract on Fusarium species from onychomycosis.
Galletti J; Tobaldini-Valerio FK; Silva S; Kioshima ÉS; Trierveiler-Pereira L; Bruschi M; Negri M; Estivalet Svidzinski TI
Future Microbiol; 2017 Nov; 12():1311-1321. PubMed ID: 28975806
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic characterization and in vitro antifungal sensitivity of Candida spp. and Malassezia pachydermatis strains from dogs.
Brito EH; Fontenelle RO; Brilhante RS; Cordeiro RA; Soares Júnior FA; Monteiro AJ; Sidrim JJ; Rocha MF
Vet J; 2007 Jul; 174(1):147-53. PubMed ID: 17188535
[TBL] [Abstract][Full Text] [Related]
31. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines.
Testore GP; Dori L; Buonomini AR; Schito GC; Soro O; Fortina G; Andreoni S; Carlone N; Tullio V; Andreoni M
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):187-92. PubMed ID: 15541604
[TBL] [Abstract][Full Text] [Related]
32. Antifungal susceptibility against yeasts isolated from pediatric oncology patients.
Kersun LS; Reilly AF; Ingram ME; Nicholaou MJ; McGowan KL
Med Mycol; 2008 Jun; 46(4):337-43. PubMed ID: 18415840
[TBL] [Abstract][Full Text] [Related]
33. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis.
Yang YL; Ho YA; Cheng HH; Ho M; Lo HJ
Infect Control Hosp Epidemiol; 2004 Jan; 25(1):60-4. PubMed ID: 14756222
[TBL] [Abstract][Full Text] [Related]
34. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
Linares MJ; Charriel G; Solís F; Casal M
Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
[TBL] [Abstract][Full Text] [Related]
35. Testing of antifungal combinations against yeasts and dermatophytes.
Harman S; Ashbee HR; Evans EG
J Dermatolog Treat; 2004 Apr; 15(2):104-7. PubMed ID: 15204161
[TBL] [Abstract][Full Text] [Related]
36. Yeasts isolated from nosocomial urinary infections: antifungal susceptibility and biofilm production.
de Freitas AR; Baeza LC; Faria MG; Dota KF; Godoy Martínez P; Svidzinski TI
Rev Iberoam Micol; 2014; 31(2):104-8. PubMed ID: 23810785
[TBL] [Abstract][Full Text] [Related]
37. [Causative agents of onychomycosis--a retrospective study].
Mügge C; Haustein UF; Nenoff P
J Dtsch Dermatol Ges; 2006 Mar; 4(3):218-28. PubMed ID: 16626318
[TBL] [Abstract][Full Text] [Related]
38. [Onychomycosis: multicentre epidemiological, clinical and mycological study].
Relloso S; Arechavala A; Guelfand L; Maldonado I; Walker L; Agorio I; Reyes S; Giusiano G; Rojas F; Flores V; Capece P; Posse G; Nicola F; Tutzer S; Bianchi M
Rev Iberoam Micol; 2012; 29(3):157-63. PubMed ID: 22198612
[TBL] [Abstract][Full Text] [Related]
39. A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination
Halvaee S; Daie-Ghazvini R; Hashemi SJ; Khodavaisy S; Rahimi-Foroushani A; Bakhshi H; Rafat Z; Ardi P; Abastabar M; Zareei M; Borjian-Boroujeni Z; Kamali Sarvestani H
Front Cell Infect Microbiol; 2021; 11():693522. PubMed ID: 34336717
[TBL] [Abstract][Full Text] [Related]
40. A study of onychomycosis in patients attending a dermatology center in Tehran, Iran.
Soltani M; Khosravi AR; Shokri H; Sharifzadeh A; Balal A
J Mycol Med; 2015 Jun; 25(2):e81-7. PubMed ID: 25952331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
